Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker ZNTL
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | William Thurman Walters 10% owner | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 4.33M | $3.50 | $15.2M Buy | Form 4 ↗ |
| Feb 10, 2026 | Vincent Vultaggio PAO and PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 6,894 | $2.42 | $16.7K Sale | Form 4 ↗ |
| Feb 9, 2026 | Vincent Vultaggio PAO and PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 3,379 | $2.39 | $8,076 Sale | Form 4 ↗ |
| Feb 9, 2026 | Ingmar Bruns Chief Medical Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 335 | $2.39 | $801 Sale | Form 4 ↗ |
| Feb 9, 2026 | Julia Marie Eastland CEO & President, Director | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 889 | $2.39 | $2,125 Sale | Form 4 ↗ |
| Feb 6, 2026 | Vincent Vultaggio PAO and PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 29,951 | $2.43 | $72.8K Sale | Form 4 ↗ |
| Feb 6, 2026 | Ingmar Bruns Chief Medical Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 2,962 | $2.43 | $7,198 Sale | Form 4 ↗ |
| Feb 6, 2026 | Julia Marie Eastland CEO & President, Director | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 7,866 | $2.43 | $19.1K Sale | Form 4 ↗ |
| Feb 3, 2026 | Vincent Vultaggio PAO and PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 556 | $2.52 | $1,401 Sale | Form 4 ↗ |
| Feb 2, 2026 | Vincent Vultaggio PAO and PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 2,540 | $2.55 | $6,477 Sale | Form 4 ↗ |
| Dec 31, 2025 | William Thurman Walters 10% owner | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 6.46M | $1.20 | $7.8M Buy | Form 4 ↗ |
| Dec 15, 2025 | David E. Goel 10% owner | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 7.50M | $1.33 | $10.0M Sale | Form 4 ↗ |
| Apr 30, 2025 | Scott Dunseth Myers Director | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 21,000 | $1.40 | $29.4K Buy | Form 4 ↗ |
| Feb 6, 2025 | Ingmar Bruns Chief Medical Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 20,000 | $2.28 | $45.6K Buy | Form 4 ↗ |
| Feb 3, 2025 | Vincent Vultaggio PAO and Interim PFO | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 2,615 | $1.71 | $4,472 Sale | Form 4 ↗ |
| Feb 3, 2025 | Mark Lackner Chief Scientific Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 14,368 | $1.71 | $24.6K Sale | Form 4 ↗ |
| Feb 3, 2025 | Andrea Paul Chief Legal Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 13,230 | $1.71 | $22.6K Sale | Form 4 ↗ |
| Jan 31, 2025 | Jan Skvarka Director | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 60,000 | $1.72 | $103.2K Buy | Form 4 ↗ |
| Jan 31, 2025 | Luke Nathaniel Walker Director | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 14,200 | $1.76 | $25.0K Buy | Form 4 ↗ |
| Jan 31, 2025 | Julia Marie Eastland CEO & President, Director | ZNTL Zentalis Pharmaceuticals, Inc. | Buy | 28,500 | $1.73 | $49.3K Buy | Form 4 ↗ |
| Jan 2, 2025 | Mark Lackner Chief Scientific Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 4,411 | $3.12 | $13.8K Sale | Form 4 ↗ |
| Oct 4, 2024 | Vincent Vultaggio Principal Accounting Officer | ZNTL Zentalis Pharmaceuticals, Inc. | Sale | 1,603 | $3.18 | $5,098 Sale | Form 4 ↗ |
22 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances